MISIS: Blood cell patches for wound healing

2023: Product Announcement

On July 7, 2023, Russian researchers from the University of MISIS and the Research Institute of Clinical and Experimental Lymphology (a branch of the Institute of Cytology and Genetics of the SB RAS) announced the creation of new bioengineering structures that accelerate wound healing.

We are talking about the use of polycaprolactone nanofibers, the surface of which is modified by a lysate obtained from platelet-rich blood plasma. This component is a natural balanced ensemble of growth factors, extracellular matrix and proteoglycans. The proposed technology makes it possible to activate the interaction of cells, stimulate their migration, proliferation and differentiation for the speedy healing of the wound.

Bioengineered touching that accelerates wound healing

It is said that untreated synthetic polymeric materials are mostly hydrophobic, as a result of which they do not adhere well to cells. To give them hydrophilic characteristics and increase biocompatibility, modification of their surface is required. Scientists conducted plasma treatment of polycaprolactone nanofibers by depositing a thin layer of polymer containing carboxyl groups on the surface of the material being developed. The introduced carboxyl groups improved biocompatibility. They can also be used to incorporate bioactive molecules into the material.

Active compounds from platelet-rich plasma fixed on the polymer support significantly enhanced cell proliferation and migration. This stimulated the work of macrophages, which allowed to regulate the cytokine background of the wound and minimize the process of inflammation.

It is said that within 10 days, the tightening of wounds accelerates by 32.1%. At the same time, complete healing with a high percentage of collagen fibers occurs on the 19th day. Introduction into the clinic of matrices based on plasma-modified polycaprolactone nanofibers containing active components from blood plasma will significantly reduce the cost of treatment and improve the quality of life of patients with neuropathic, neuroischemic and diabetic ulcers.^[1]

Notes